Eton Pharmaceuticals Inc (NASDAQ:ETON) saw unusually-strong trading volume on Tuesday . Approximately 2,215,807 shares traded hands during trading, an increase of 3,203% from the previous session’s volume of 67,076 shares.The stock last traded at $6.43 and had previously closed at $5.83.
Several analysts have issued reports on ETON shares. HC Wainwright restated a “buy” rating and set a $18.00 price target on shares of Eton Pharmaceuticals in a research report on Monday, August 5th. B. Riley assumed coverage on shares of Eton Pharmaceuticals in a report on Friday, September 20th. They set a “buy” rating and a $13.50 target price for the company. Lake Street Capital assumed coverage on shares of Eton Pharmaceuticals in a report on Monday, August 5th. They set a “buy” rating for the company. Zacks Investment Research lowered shares of Eton Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Tuesday, October 8th. Finally, ValuEngine upgraded shares of Eton Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Thursday, August 1st. One investment analyst has rated the stock with a hold rating and four have assigned a buy rating to the stock. The stock has an average rating of “Buy” and a consensus price target of $12.83.
The company has a quick ratio of 11.48, a current ratio of 11.48 and a debt-to-equity ratio of 0.01. The stock’s fifty day moving average price is $6.14 and its two-hundred day moving average price is $6.96. The company has a market capitalization of $107.64 million and a PE ratio of -1.11.
In other news, CEO Sean Brynjelsen bought 5,000 shares of the company’s stock in a transaction dated Tuesday, August 13th. The stock was bought at an average cost of $6.15 per share, for a total transaction of $30,750.00. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Corporate insiders own 13.46% of the company’s stock.
A number of hedge funds have recently added to or reduced their stakes in ETON. BlackRock Inc. raised its stake in Eton Pharmaceuticals by 181.2% in the second quarter. BlackRock Inc. now owns 26,092 shares of the company’s stock worth $206,000 after buying an additional 16,813 shares in the last quarter. Vanguard Group Inc. raised its stake in Eton Pharmaceuticals by 6.7% in the second quarter. Vanguard Group Inc. now owns 28,762 shares of the company’s stock worth $227,000 after buying an additional 1,800 shares in the last quarter. Finally, Tower Research Capital LLC TRC raised its stake in Eton Pharmaceuticals by 122.5% in the second quarter. Tower Research Capital LLC TRC now owns 3,139 shares of the company’s stock worth $25,000 after buying an additional 1,728 shares in the last quarter. 9.95% of the stock is owned by institutional investors.
Eton Pharmaceuticals Company Profile (NASDAQ:ETON)
Eton Pharmaceuticals, Inc, a specialty pharmaceutical company, focuses on developing and commercializing pharmaceutical products. It primarily focuses on liquid products, including injectable, oral liquid, and ophthalmic products. The company develops EM-100, an ophthalmic product for the treatment of allergic conjunctivitis; ET-202 and ET-203, which are injectable product candidates for use in the hospital setting; ET-103, an oral liquid product candidate for hypothyroidism; ET-101, ET-102, and ET-104, which are oral liquid product candidates for neurological indications; and CT-100, a synthetic corticotropin therapeutic candidate for rheumatoid arthritis.
Read More: Why is the conference call important?
Receive News & Ratings for Eton Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eton Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.